A 13-week, randomized, double-blind, placebo-controlled, monotherapy trial of pregabalin (BID) in patients with fibromyalgia

Trial Profile

A 13-week, randomized, double-blind, placebo-controlled, monotherapy trial of pregabalin (BID) in patients with fibromyalgia

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Pregabalin (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Nov 2016 Results of post-hoc analysis from pooled data of this and other two studies presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 14 May 2016 Results of a pooled analysis from NCT00645398, NCT00230776, NCT00333866 trials (n=2228) presented at the 35th Annual Scientific Meeting of the American Pain Society
    • 03 May 2014 Results from a pooled analysis presented at the 33rd Annual Scientific Meeting of the American Pain Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top